

AX PHARMACEUTICAL CORP- tiopronin powder
AX Pharmaceutical Corp

Caution: For prescription compounding use only.
Use according to practitioner's prescription.
Federal law prohibits dispensing without prescription.
Keep tightly closed in a cool place



AX Pharmaceutical Corp

Tiopronin

Retest date: Nov 28, 2020

500g

Original Reference: 20171204

CAS: 1953-02-2

NDC: 62157-507-01

Repackaged by: AX Pharmaceutical Corp

Lot: C350-17K29SH

100 West Beaver Creek Road, Unit 12, Richmond Hill, ON Canada L4B 1H4 Fax: 416 852 1618

Toll free: 1 866 305 0566

May be harmful if inhaled.
Do not breathe dust from your eyes/nose/mouth.
Wash hands thoroughly after handling this product. Do not eat, drink, or smoke while using this product. Contaminated work clothing should not be removed to the environment. Wear protective gloves/eye protection/face shield. If SWALLOWED, call a POISON CENTER or doctor immediately. If ON SKIN, wash with plenty of water. Get medical advice/attention if you feel unwell. If in eyes, rinse cautiously with water for several minutes. Collect spillage. Do not get inside clothing. Remove contaminated clothing or shoes if appropriate. Wash exposed skin.

Warning

AX PHARMACEUTICAL CORP

tiopronin powder

Product Information

Product Type	BULK INGREDIENT	Item Code (Source)	NDC:62157-507
Route of Administration	NOT APPLICABLE		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
TIOPRONIN (UNII: C5W04GO6 1S) (TIOPRONIN - UNII:C5W04GO6 1S)	TIOPRONIN	495 g in 500 g

Inactive Ingredients

Ingredient Name	Strength
WATER (UNII: 059QF0KO0R)	

Product Characteristics

Color	white	Score	
Shape		Size	
Flavor		Imprint Code	
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:62157-507-01	500 g in 1 JAR	12/12/2017	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
bulk ingredient for animal drug compounding		12/12/2017	

Labeler - AX Pharmaceutical Corp (202924858)

Revised: 12/2017

AX Pharmaceutical Corp